Overview

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

Status:
Completed

Trial end date:
2017-04-04

Target enrollment:
0

Participant gender:
All

Summary

This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Gilead Sciences

Criteria

Key Inclusion Criteria:

- Estimated glomerular filtration rate (Cockcroft-Gault method)using actual body weight
of ≥ 50 mL/min at time of entry into registry

- Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV)

- No history of solid organ or bone marrow transplant

- Currently receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy
within 6 months of inclusion into registry

Note: Other protocol defined Inclusion/Exclusion criteria may apply.